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Immunotherapy in Gynecological 
Malignancies
Neha Sharma and Deepti Sharma
Abstract
Cancer immunotherapy is one of the most upcoming treatment strategies emerg-
ing as a fascinating option in the management of advanced gynecological malignan-
cies. The development of immune-based antitumor approaches has led to safer 
treatment options that give fruitful results in these malignancies. In this chapter we are 
focusing on immune-based treatment in the management of gynecological cancers like 
cervical cancer, endometrial cancer, ovarian cancer, and vaginal and vulvar cancer. 
We are also discussing the clinical studies that have been conducted or are currently 
underway which are exploring these immune strategies that are developing as a logical 
overture for the treatment of advanced cancers including gynecological cancers.
Keywords: gynecological malignancy, immunotherapy, immune checkpoint 
inhibitors, cervical cancer, ovarian cancer, endometrial cancer
Cancer immunotherapy is emerging as an attractive strategy among different 
therapeutic options over the past years, and also the treatment of many advanced 
malignancies has been revolutionized with the development of immune-based 
antitumor therapies. The advent of targeted immune therapies leading to success-
ful outcomes in other malignancies has led to an increase in the number of clinical 
trials using these interventional strategies in patients with gynecological cancer. 
Generally, the role of immunotherapy is either to reactivate the immune response or 
to diminish the tumor-directed immune inhibition.
There are three stages of the dynamic process of immunoediting, also known as 
the three Es: an early elimination phase with the activation of an innate and adop-
tive immune response, an equilibrium phase where the isolated tumor cells are able 
to endure immune incursion, and an immune escape phase that the cancer cell vari-
ants can alter their genomic or antigenic phenotype or they are under the control 
of immunoregulatory phenomena to survive in the immunosuppressive medium. 
In order to activate tumor-directed immune responses, recent immune therapies 
have consisted of several approaches, including adoptive cell transfer (ACT), cancer 
vaccines, and immune checkpoint inhibitors.
Cervical cancer is unique among gynecologic malignant tumors because of its well-
established and causative risk factor, chronic HPV infection. The infectious etiology of 
cervical cancer has led to effective vaccines for prevention; however, advanced stage/
metastatic disease remains a principal cause of gynecologic cancer mortality in much 
of the world. The implementation of antiangiogenic therapy has greatly improved the 
treatment for relapsed/advanced disease over the last 5 years. Several clinical trials 
including CheckMate 358 and KEYNOTE-028 and KEYNOTE-158 are evaluating the 
role of immune checkpoint inhibitors in the treatment of cervical cancer.
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In endometrial cancer, patients with advanced or disseminated recurrent disease 
have a poor prognosis, and most patients with peritoneal recurrence are considered 
incurable. Platinum and taxane chemotherapy produces response rates of 40–60%, 
which decreases to 20% for second-line drugs. So there is a need for development of 
more effective treatment for patients having advanced disease.
Approximately 25% of endometrial tumors are characterized by defects in the 
DNA mismatch repair system manifested by errors in DNA replication of trinucleo-
tide repeat regions, commonly referred to as microsatellite instability. These defects 
in mismatch repair (MMR) also result in a high somatic mutation rate and accord-
ingly increased number of neoantigens in these MMR-deficient tumors. In endome-
trial cancer, the presence of high microsatellite instability (MSI-H) has become an 
area of interest for use of immune checkpoint inhibitors.
For several reasons ovarian cancer is an ideal tumor type for which to consider an 
immunomodulatory management approach. Firstly, there is no negative impact of 
cancer itself on immunoregulatory cells that may be present within the bone marrow or 
other body locations. Secondly, while standard cytotoxic therapy of ovarian cancer can 
result in a depression in the number of immunoregulatory cell, these effects are gener-
ally modest in extent and short in duration. Lastly, it is common for patients with ovar-
ian cancer to maintain a quite reasonable performance status and satisfactory nutrition.
A majority of ovarian cancer patients respond to cytotoxic chemotherapy and 
invariably are free from disease for periods varying from months to several years. 
This time interval can be exploited for required “activation” of immune defense 
mechanisms, either by using a tested vaccination strategy or any other form of 
immune modulation.
Multiple studies involving immune checkpoint inhibitors, conducted in 
advanced endometrial cancer, ovarian cancer, and cervical cancer, have shown 
promising preliminary results. But similar to that seen in other tumor types, contin-
ued work will need to focus on identifying those subsets of patients that will benefit 
from these therapies as these treatments are not without significant toxicities.
1. Introduction
The immune system plays an important role in cancer pathogenesis. Numerous 
clinical trials and multiple researches dedicated to study therapies that involve the 
immune system to favorably impact the disease course in various malignancies have 
not only shown improved patient survival but also diversified the whole cancer 
management scenario by approval of the use of various immunotherapeutic agents 
in advanced malignancies [1].
Since cancer immunotherapy has emerged as an effective and appealing thera-
peutic option among other different therapeutic strategies and has been proven 
competent against multiple malignancies, it has led to an increase in research on 
immunomodulatory approaches in gynecological malignancies [2].
The ongoing research on the understanding of tumor biology and immunology has 
led to improved comprehension of mechanisms of immune recognition, regulation, 
and tumor escape that has provided new approaches for cancer immunotherapy [3].
2. Role of immune system in cancer
The principal role of the immune system is against foreign pathogens and infec-
tions. It is further classified as cellular and humoral immune systems, mediated by 
T and B lymphocytes and their products, respectively.
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The initial innate immunity is nonspecific, and the adaptive immune response is 
the specialized defense. Both the strategies work in different manner. They employ the 
cellular immunity which has a rather fast response in eradicating intracellular microbes 
through the recognition of antigens, activation of antigen-presenting cells (APCs), 
and activation and proliferation of T cells. They also need humoral immunity mediated 
via antibodies produced by B cells for neutralizing toxins and act against infections. 
Where innate immunity works by releasing signals essential to stimulate responses 
from both T cells and B cells [4], the adaptive immune system is mainly consists of B 
cells, CD8+ cytotoxic T cells, as well as CD4+ helper T cell [5].
The immune system in tumor cells has a dynamic relationship, in which either 
it can identify or control tumor cells in a process called cancer immunosurveillance 
or cause tumor progression through chronic inflammation, immunoselection of 
poorly immunogenic variants, and suppressing antitumor immunity [6]. There are 
three stages of this dynamic process called immunoediting. The first is the elimina-
tion phase in which innate and adaptive immunity works together to identify and 
eliminate the cancer cells before they become clinically apparent [7]. If the cancer 
cells are not eliminated, they enter the second phase which is equilibrium. It can 
last from months to years. Here the cancer cells persist, but outgrowth is prevented 
by the immune system. Lastly the escape phase is in which either the cancer cell 
variants survive in the immunosuppressive microenvironment by altering genetic 
or antigenic phenotype or under the control of immunoregulatory phenomena. [8] 
In order to activate tumor-directed immune responses, recent immune therapies 
have consisted of several approaches, including adoptive cell transfer (ACT), cancer 
vaccines, and immune checkpoint inhibitors.
Gynecological cancers are a group of malignancies that involve different organs 
that comprise the female reproductive system. The most common types of gyne-
cologic malignancies are cervical cancer, ovarian cancer, and endometrial cancer. 
Other less common gynecological malignancies arise from the vagina, vulva, and 
fallopian tubes [9].
3. Cervical cancer
Cervical cancer represents 6.6% of all female cancers. It is the fourth most 
common cancer in women with an estimated 570,000 new cases in 2018. 
Approximately 90% of deaths from cervical cancer occur in underdeveloped and 
developing countries [10]. Cervical cancer has emerged as a preventable disease 
due to currently employed screening tests which have highlighted HPV infection 
as an etiological factor. Although significant progress has been made in screen-
ing and prevention of cervical cancer, the 5-year overall survival remains 66% 
[11]. For cases diagnosed at an early stage, the recurrence rates vary between 10 
and 20%, but for advanced cases, the rate of recurrence reaches up to 70% [12]. 
There is a need to improve outcomes, and immunotherapy could offer this pos-
sibility. The recognition of human papilloma virus as an etiological agent has 
greatly improved the understanding of the disease and led to improved strategies 
in prevention of cervical cancer [13]. The infectious etiology of cervical cancer 
has led to effective vaccines for prevention; however, advanced stage/metastatic 
disease remains a principal cause of gynecologic cancer mortality. Currently there 
are three licensed HPV prophylactic vaccines, namely, bivalent vaccine cervarix 
against HPV16/18, Gardasil against HPV-6/11/16/18, and Gardasil9, a nonavalent 
HPV-6/11/16/18/31/33/45/52/58 vaccine. All are based on on-infectious recombi-
nant type-specific L1 capsid proteins assembled into viral-like particles (VLPs) as 
immunogens [14].
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There is a huge unmet need for the treatment for women having advanced/recur-
rent cancer after standard chemotherapy and immunotherapy aims to fill that void, 
through therapies that harness a patient’s own immune system to attack the cancer.
4. Cancer vaccines in cervical cancer
Cancer vaccines are used to mediate immune response by activating T cells 
which can specifically recognize cancer cells by tagging them with tumor-specific 
antigens E6 and E7. These antigen-tagged tumor cells are recognized by antigen-
presenting cells and killed by cytotoxic T cells [15].
Live vector vaccines are highly immunogenic vaccines which can stimulate 
mucosal as well as humoral and/or cellular systemic immunity. They present E6 and 
E7 to APC to cause immune response through major histocompatibility complex 
MHC I [16]. Although they are attenuated vaccines, still care has to be taken before 
administering it in immunocompromised individuals. ADXS11-001 is a type of live 
attenuated vaccine that uses Listeria monocytogenes (Lm), a gram-positive intracel-
lular bacterium as bacterial vector. It secretes HPV-16 E7 antigen fused to a nonhe-
molytic fragment of Lm protein listeriolysin O [17].
The following studies have been conducted (Table 1):
Study 
name
Patient 
cohort
Treatment schedule Response Toxicity
Maciag 
et al. [18]
Phase I trial
n = 15
Recurrent 
or 
metastatic 
disease
DL1: ADXS11-001 
1 × 109 two doses 
every 21 days
DL2: ADXS11-001 
3.3 × 109 two doses 
every 21 days
DL3: ADXS11-001 
1 × 1010 two doses 
every 21 days
Stable disease in 7 
patients
Pyrexia (100%), 
vomiting 60%, 
pain (57%), chills, 
anemia (53%)
Grade 3: 40% 
(6 pts)
Ghamande 
et al. [19]
Phase I
n = 9
Recurrent 
or 
metastatic 
disease
DL1: ADXS11-001 
5 × 109 thrice weekly 
during 12 weeks DL2: 
ADXS11-001 1 × 1010 
thrice weekly during 
12 weeks
— TRAE: 75%
AE: 99% Grade 1 
and 2
Grade 3: 
chills, vomit, 
hypotension, 
tachycardia, fever, 
and nausea
Basu et al. 
[20]
Phase II
n = 109
Advanced 
cervical 
cancer
Arm 1 ADXS11-001 
monotherapy
Arm 2 ADXS11-
001 with cisplatin 
combination
Median progression-
free survival (6.10 
vs. 6.08 months) and 
the overall response 
rate (17.1% vs. 14.7%) 
were similar for both 
groups
More adverse 
effects in arm 2
Huh et al. 
[21] (GOG 
0265)
Phase II
n = 26
Recurrent 
or 
metastatic 
disease
ADXS11-001 1 × 109 
every 28 days for 3 
doses
Mean 12 months 
survival: 38.5%
Median OS: 6.2 
months
AE: 91% Grade 1 
and 2
TRAE: 38%: 
nausea, vomiting, 
chills, fatigue, and 
fever
Table 1. 
Role of vaccination in HPV-associated cervical cancer.
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4.1 Peptide-based vaccines in cervical cancer
Refer Table 2.
4.2 Dendritic vaccines in cervical cancer
Refer Table 3.
Study 
name
Patient 
cohort
Treatment 
schedule
Response Toxicity
Welters 
et al. [22]
Phase II 
adjuvant
n = 6
Stage IB1 and 
HPV16+
HPV16 E6 E7 
SLP vaccine
Vaccine-enhanced 
number and 
activity of HPV16-
specific CD4+ and 
CD8+ cells
Grade 1 and Grade 2: 
local pain, fever, flu-like 
symptoms, swelling, itching, 
burning eyes
Poelgeest 
et al. [23]
Phase II
n = 31
Recurrent or 
metastatic 
disease
HPV16 E6-E7 
SLP vaccine 
300 g for four 
doses every 
21 day
Median OS: 12.6 
months no tumor 
regression or delay 
of progression
Grade 1 and Grade 2: fever, 
fatigue, headache, flu-like 
symptoms, chills, nausea, 
swelling extremities, 
rash, vomiting, tingling 
extremities, and injection 
site pain
Table 2. 
Peptide-based vaccine in cervical cancer.
Study name Patient 
cohort
Treatment schedule Response Toxicity
Ramanathan 
et al. [24]
Phase I
n = 14
Recurrent 
or 
metastatic 
disease
Arm 1: placebo three doses 
every 14 days
Arm 2: unprimed DC three 
doses 1 × 106 cells every 
14 days
Arm 3: primed DC three 
doses 1 × 106 cells every 
14 days
SD in Arm 3 Grade 1 and 
Grade 2: itching 
at injection site, 
fever, chills, 
abdominal 
discomfort, 
vomit, ALP 
increased
Ferrara et al. [25]
Phase I
n = 15
Recurrent 
or 
metastatic 
disease
Analogous dendritic 
cells pulsed with HPV E7 
protein
Serological 
response in 
3 pts
Cellular 
response in 
4 pts
No objective 
clinical 
response
Santin et al. [26]
Phase I
n = 10
Stage IB or 
IIA
DL1: HPV16/18 E7 antigen-
pulsed DC5 × 106 for five 
doses every 21 days
DL2: HPV16/18 E7 antigen-
pulsed DC10 × 106 for five 
doses every 21 days
DL3: HPV16/18 E7 antigen-
pulsed DC15 × 106 for five 
doses every 21 days
CD4+ T-cell 
response in all 
patients
Mild swelling 
and erythema at 
the injection site
Table 3. 
Dendritic vaccine in cervical cancer.
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5. Immune checkpoint inhibitors in cervical cancer
5.1 PD1/PDL1 inhibitors
Programmed cell death protein-1/programmed death ligand-1 immunoregula-
tory axis is a promising target for cervical cancer treatment [27]. Pembrolizumab 
is a humanized monoclonal immunoglobulin G4 (IgG4) kappa isotype antibody 
targeting PD-1 (Table 4).
Other ongoing trials of pembrolizumab include PAPAYA Trial [30] which is a 
phase I study involving Stage Ib to Stage IV cervical cancer. The treatment schedule 
includes intravenous pembrolizumab followed by cisplatin-based chemoradio-
therapy and brachytherapy and additional pembrolizumab after radiation. Another 
phase II trial with pembrolizumab followed by chemoradiotherapy and brachy-
therapy is also open for recruitment [31].
Nivolumab is a human IgG4 monoclonal antibody that causes stimulation of 
PD1 pathway-mediated immune response inhibition by binding to the PD-1 recep-
tor and blocking its interaction with PD-L1 and PD-L2. [32] Checkmate 358 trial is a 
phase I/II trial by Hollebecque et al. in 19 patients of cervical cancer which studied 
nivolumab 240 mg every 2 weeks and showed ORR was 20.8% and disease control 
rate was 70.8%. Responses were observed regardless of PD-L1 expression, HPV 
status, and number of prior therapies [33].
Other trials of nivolumab include NRG-GY002, a phase II trial in recurrent or 
metastatic breast cancer [34]. A trial of nivolumab with HPV 16 SLp vaccine in 
HPV 16 positive cervical cancer is also underway [35].
Other checkpoint inhibitors under investigation include atezolizumab which is 
a fully humanized monoclonal antibody IgG1 isotype PD-L1. It is being studied to 
assess the safety and efficacy in combination with cyclophosphamide/carboplatin 
in gynecological cancer including cervical cancer in phase Ib PRO-LOG study [36]. 
Another phase II study is ongoing to study the synergistic action of antiangiogenic 
therapy with immunotherapy by combining bevacizumab with atezolizumab in 
women with recurrent or metastatic cervical cancer [37, 38],
Durvalumab is a human IgG1 monoclonal antibody that blocks the action of 
PD-L1 with PD1 and CD 80. It is being studied along with tremelimumab, which 
is an antibody against CTLA4 in patients who have failed to respond or relapsed to 
standard treatment [39].
5.2 CTLA-4 inhibitors
Ipilimumab is a fully human monoclonal IgG1κ antibody which acts against 
the cytotoxic T lymphocyte antigen-4 (CTLA-4). CTLA4 is an immune-inhibitory 
Study name Patient cohort Treatment 
schedule
Response Toxicity
Keynote 028
Frenel et al. [28]
Phase Ib
n = 24
Patients having 
metastatic 
disease in PD 
L1 > =1%
Pembrolizumab 
10 mg/kg every 
2 weeks up to 
2 years
ORR = 12.5%
6 months PFS 13%
OS 66.7%
(preliminary results)
75% pts with 
treatment-related 
adverse effects
20.8% with Grade 3 
toxicity
Keynote 0158
Schellens et al. 
[29]
Phase II
n = 47
Metastatic 
disease
Pembrolizumab 
200 mg thrice 
weekly to 2 years
ORR 17% 
(independent of 
tumor PD L1 status)
Not reported
Table 4. 
PD1/PDL1 inhibitors in cervical cancer.
7Immunotherapy in Gynecological Malignancies
DOI: http://dx.doi.org/10.5772/intechopen.90711
molecule which is expressed in activated T cells and in suppressor T regulatory 
cells [40] (Table 5).
5.3 Adoptive cell transfer therapy
Adoptive cell transfer therapy using autologous tumor-infiltrating lymphocytes is 
emerging as a promising treatment modality in immunotherapy for various cancers. 
There are two types of adoptive cell therapy which includes chimeric antigen recep-
tor T-cell (CAR T-cell) therapy and tumor-infiltrating lymphocyte (TIL) therapy.
Chimeric antigen receptor (CAR) T-cell therapy involves genetically engineered 
patient’s autologous T cells that causes them to express a CAR specific for a tumor 
antigen. These cells are extracted, further divided, and reinfused back into the 
patient [43].
A trial was conducted by Lu et al. which evaluated adoptive CD4+ T-cell therapy 
in solid metastatic cancer. It had two patients of metastatic cervical cancer, out of 
which one patient had objective complete response [44].
There is a trial ongoing to test the safety, feasibility, and efficacy of CAR T-cell 
immunotherapy in patients who have GD@, PSMA, Muc1, mesothelin, or positive 
cervical cancer markers by Chang et al. [45].
TIL therapy predates the CAR T-cell therapy, and the basic principle involves 
the ex vivo culture of tumor specimens which have been resected and expansion 
of tumor-infiltrating lymphocytes (TILs) with interleukin-2. Selected T cells of a 
preferred antigen specificity and phenotype can be identified in vitro and divided. 
The number of antigen-specific T cells in peripheral blood after this method usu-
ally exceeds by far that possible by current vaccine treatment strategies alone. In 
addition, adoptive T cells appear more effective in inducing tumor regression than 
lymphocytes generated by vaccines, suggesting greater ability to overcome tumor-
mediated immune evasion mechanisms [46].
Study 
name
Patient cohort Treatment schedule Response Toxicity
Lheureux 
et al. [41]
Phase I/II
n = 42
Recurrent or 
metastatic disease
Phase I: ipilimumab 
3 mg/kg every 21 days 
for four doses
Phase II: ipilimumab 
10 mg/kg every 21 days 
for four doses and four 
cycles (same dose) every 
12 weeks
Median 
PFS 
2.5 months
Grade 3 toxicity: 
diarrhea, colitis
GOG9929 
study
Mayadev 
et al. [42]
Phase I
n = 34
FIGO IB2/IIA 
or IIB/IIIB/IVA, 
positive nodes
Weekly cisplatin  
40 mg/m2 during 
6 weeks and extended 
field radiotherapy. If no 
progression 2–6 weeks 
after
DL1: ipilimumab  
3 mg/kg for four doses 
every 21 days
DL2: ipilimumab  
10 mg/kg for four doses 
every 21 days
DL3: ipilimumab  
10 mg/kg for four doses 
every 21 days
1 year DFS 
74%
Grade 1 and Grade 2: 
rash, endocrinopaties, 
gastrointestinal 
toxicity
Grade 3: 16% including 
lipase increased, 
neutropenia, and rash
Table 5. 
CTLA4 inhibitors in cervical cancer.
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Stevanovic et al. [47] conducted a trial on 17 patients of metastatic cervical 
cancer who received high-dose lymphocyte-depleting chemotherapy followed by 
aldesleukin. Patients were treated with a single infusion of human papillomavirus 
(HPV) E6 and E7 reactivity (HPV-TILs). Three of nine patients experienced objec-
tive tumor responses (two complete responses and one partial response).
6. Endometrial cancer
Endometrial cancer is the 4th most commonly occurring cancer in women and the 
15th most commonly occurring cancer overall. There were over 380,000 new cases 
in 2018 [48]. In women with advanced and recurrent cancer, the prognosis is consid-
ered very poor. Unfortunately, there are limited treatment options for advanced or 
recurrent endometrioid endometrial cancer. However, with the advent of immuno-
therapy, immune checkpoint inhibitors have shown promising results in these cases. 
Study 
name
Patient cohort Treatment 
schedule
Response Toxicity
Ott 
et al. 
[53]
n = 24
Locally advanced or 
metastatic PD-L1-
positive endometrial 
cancer
Pembrolizumab 
10 mg/kg every 
2 weeks for up 
to 24 months or 
until progression 
or unacceptable 
toxicity
Three (13%) 
patients achieved 
confirmed partial 
response. Three 
additional patients 
achieved stable 
disease, with a 
median duration of 
24.6 weeks
Grade 3 treatment-
related AEs were 
reported in four 
patients
Makker 
et al. 
[54]
Phase II
n = 53
Metastatic 
endometrial 
cancer unselected 
for microsatellite 
instability or PD-L1
20 mg oral 
lenvatinib daily 
plus 200 mg 
intravenous 
pembrolizumab 
every 3 weeks, 
until progression 
or unacceptable 
toxicity
Patients had an 
objective response 
at week 24
Serious treatment-
related adverse 
events occurred 
in 16 (30%) 
patients, and one 
treatment-related 
death was reported 
(intracranial 
hemorrhage)
Santin 
et al. 
[55]
n = 2
Pretreated 
polymerase 
ε (POLE) 
ultramutated and 
MSH6 hypermutated 
recurrent 
endometrial tumors
refractory to surgery, 
radiation, and 
chemotherapy
Anti-PD1 immune 
checkpoint 
inhibitor 
nivolumab 3 mg/
kg biweekly
Both patients 
demonstrated a 
remarkable clinical 
response to the 
anti-PD1 immune 
checkpoint 
inhibitor 
nivolumab
No Grade 3 or 
higher side effects 
reported
Fleming 
et al. 
[56]
n = 15
Previously 
treated recurrent 
endometrial cancer
Atezolizumab 
1200 mg or 15 mg/
kg IV q3w was 
administered until 
toxicity or loss of 
clinical benefit
ORR was 13% 
(2/15)
Of the remaining 
pts, two had SD, 
nine had PD, 
and two were 
non-evaluable
Seven (47%) pts 
had any related 
AE, mainly 
G1-2 (5 pts). No 
G4-5-related AEs 
occurred
Table 6. 
Immunotherapy in endometrial cancer.
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Microsatellite instability-high (MSI-H) status, tumor mutation burden, and high 
PD-L1 expression have been associated with higher response rates to this therapy [49].
Approximately 25% of endometrial cancer show microsatellite instability which 
is caused by defects in mismatch repair genes. These defective MMR genes lead 
to high somatic mutation rates, thereby increasing the number of neoantigens in 
MMR-deficient tumors [50].
Endometrial cancer has been subdivided into four prognostically distinct 
molecular subgroups based on the findings of the cancer genome atlas, namely, 
polymerase epsilon (POLE) ultramutated, MSI hypermutated, copy-number (CN) 
low, and CN high [51].
The ultramutated POLE subgroup and MSI hypermutated subgroup have 
immune-rich microenvironment and high mutation load. Evidence has supported 
over-expression of the PD-1/PD-L1 pathway in these molecular subtypes, and 
therefore, PD1/PD L1-targeted immunotherapy has a role in these tumors [52] 
(Table 6).
An ongoing phase II, two group trials are studying the role of avelumab 
in POLE-mutated endometrial cancer and MSS-mutated endometrial cancer. 
Avelumab is administered at 10 mg/kg as 1-hour IV infusion every 2 weeks until 
disease progression or unacceptable toxicity. Sixteen patients are enrolled in each 
cohort in the first stage. The preliminary results are yet to be published [57].
6.1 Anticancer vaccines in endometrial cancer
The following studies have been conducted (Table 7).
7. Ovarian cancer
Ovarian cancer accounts for 2.5% of all malignancies among females but 5% of 
female cancer deaths because of low survival rates, largely driven by late-stage diag-
noses [60]. There were nearly 300,000 new cases in 2018. Ovarian cancer is con-
sidered to be an ideal type of tumor which can be dealt with immunomodulatory 
Study name Patient cohort Treatment 
schedule
Response Toxicity
Ohno et al. 
[58], phase II
n = 12
WT1/human 
leukocyte 
antigen (HLA)-
A*2402-positive 
gynecological 
cancer
Intradermal 
injections of a 
HLA-A*2402-
restricted, 
modified 9-mer 
WT1 peptide every 
week for 12 weeks
Stable disease in three 
patients and progressive 
disease in nine patients. 
The disease control rate 
was 25.0%
Local 
erythema 
occurred 
at the WT1 
vaccine 
injection site
Coosemans 
et al. [59]
n = 6
Pretreated 
patients with 
uterine cancer
Four times 
weekly vaccines 
of autologous 
dendritic 
cells (DCs) 
electroporated with 
WT1 mRNA
Three out of four 
human leucocyte 
antigen-A2 (HLA-
A2)-positive patients 
showed an oncological 
response. Two HLA-A2-
negative patients did 
not show an oncological 
or an immunological 
response
One patient 
had a local 
allergic 
reaction
Table 7. 
Anticancer vaccines in endometrial cancer.
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approach as the disease does not negatively affect the immunoregulatory cells in the 
bone marrow or other locations of the body, and the patients suffering from ovarian 
cancer maintain a relatively good performance status even in later stages, so immu-
notherapy can be used as a potential treatment option in these patients. Cytotoxic 
chemotherapy given in ovarian cancer can negatively impact the immunoregula-
tory cells, but the effect is short lasting. Further the patients who are in advanced 
stages, if they respond to standard treatment of ovarian cancer, have a relatively 
long disease-free period which is substantial for the activation of immune defense 
mechanism either by cancer vaccines or by immunomodulator drugs [61].
7.1 Immune checkpoint inhibitors in ovarian cancer
The first published data supporting checkpoint inhibitors as a potentially 
valuable therapeutic option in ovarian cancer were observed in the trials of the 
anti-PD-1 antibody nivolumab and the anti-PD-L1 antibody BMS-93655 [62]. Other 
studies are as follows (Table 8).
Study 
name
Patient cohort Treatment schedule Response Toxicity
Hamanishi 
et al. [63]
Phase II
n = 20
Platinum-resistant 
ovarian cancer
IV nivolumab every 
2 weeks at a dose of 1 
or 3 mg/kg
Overall response 
rate was 15%, 
and the disease 
control rate was 
45%
Grade 3 or 
4 TRAE 
in 40% 
patients
Disis et al. 
[64]
Phase Ib
n = 124
Recurrent/refractory 
ovarian cancer
Avelumab 10 mg/kg 
IV every 2 weeks
ORR was 
9.7% based 
on 12 partial 
responses; 6 
were ongoing. 
Stable disease 
was observed in 
55 pts (44.4%); 
disease control 
rate was 54.0%
Grade 3 or 4 
TRAEs were 
reported in 
6.5%
Varga et al. 
[65]
Phase Ib
n = 26
Advanced ovarian 
cancer
Pembrolizumab 
10 mg/kg was given 
every 2 weeks for 
up to 2 years or 
until confirmed 
progression or 
unacceptable toxicity
The best overall 
(confirmed) 
response was 
11.5%. 6/26 
(23.1%) had 
evidence 
of tumor 
reduction; 3 
had a tumor 
reduction of at 
least 30%
Drug-
related AEs 
occurred in 
69.2% of pts
Lee et al. 
[66]
Phase I/II
n = 12
BRCA positive with 
ovarian cancer
Durvalumab at 
1500 mg every 
4 weeks plus olaparib 
at 300 mg twice daily 
and durvalumab 
at 1500 mg every 
4 weeks plus cediranib 
at 20 mg 5 days 
on/2 days off per week
ORR of 17% and 
disease control 
rate of 83%
Grade 3 or 4 
TRAEs were 
reported in 
75% patients
Table 8. 
Immune checkpoint inhibitors in ovarian cancer.
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Ongoing trials include JAVELIN Ovarian 200 is the first phase III trial, which is 
a three-arm trial, comparing avelumab administered alone or in combination with 
pegylated liposomal doxorubicin versus pegylated liposomal doxorubicin alone in 
patients with platinum-resistant/refractory recurrent ovarian cancer [67].
NCT02839707 is undergoing trial which is comparing pegylated liposomal 
doxorubicin with atezolizumab and/or bevacizumab in refractory ovarian  
cancer [68].
A phase II study by Wenham et al. [69] is studying combination of weekly 
paclitaxel and an anti-PD-1 (pembrolizumab). The primary endpoint of this study 
is a 6-month progression-free survival rate.
ATALANTE trial is an ongoing phase III study to assess the efficacy of atezoli-
zumab in combination with platinum-based chemotherapy plus bevacizumab 
administered concurrent to chemotherapy and in maintenance [70].
CheckMate 032 study trial to study the safety and efficacy of nivolumab as a 
single agent or in combination with ipilimumab is currently underway [71].
Similar trial in which nivolumab with or without ipilimumab in treating patients 
with persistent or recurrent epithelial ovarian is being studied by the National 
Cancer Institute [72].
A phase II trial to determine the median immune-related progression-free sur-
vival (irPFS) in combination of an anti-CTLA-4 antibody (tremelimumab) with an 
anti-PD-L1 antibody (durvalumab) versus their sequential use in platinum-resistant 
epithelial ovarian cancer is also currently ongoing [73].
Multiple other trial are using immune checkpoint inhibitors in initial therapy to 
improve progression-free survival like durvalumab or pembrolizumab with stan-
dard paclitaxel and carboplatin therapy, where pembrolizumab is used as adjuvant 
therapy after surgery [74]. The role of immune checkpoint inhibitors as mainte-
nance therapy is also under investigation with JAVELIN Ovarian 100 phase II study 
of avelumab (anti-PD-L1) as maintenance after standard therapy or in combination 
with standard therapy and then continued as maintenance treatment [75].
7.2 Cancer vaccines in ovarian cancer
Various types of cancer vaccines are studied for the treatment of ovarian cancer.
The cancer testis antigen, NY ESO1, is most frequently expressed in epithelial 
ovarian cancer, and vaccine against it has shown induced T-cell-specific immunoge-
nicity [76]. Since NY-ESO-1 is regulated by DNA methylation, it was hypothesized 
that DNA methyltransferase (DNMT) inhibitors may augment NY-ESO-1 vaccine 
therapy. Decitabine is a hypomethylating agent that inhibits DNA methyltransfer-
ase. A phase I trial was conducted to study dose escalation of decitabine in addition 
to NY-ESO-1 vaccine and doxorubicin liposome in 12 patients with relapsed epithe-
lial ovarian carcinoma. The results showed stable disease or partial response in six 
patients [77].
Sabbatini et al. conducted a phase I trial in 28 patients which showed that in order 
to enhance the immunogenic response to NY-ESO1, the addition of immune modula-
tion agents to the vaccine preparation such as Montanide and immunostimulants 
such as the toll-like receptor (TLR) ligand poly-ICLC (polyinosinic-polycytidylic 
acid—stabilized by lysine and carboxymethylcellulose) can be considered [78].
Other antigen under investigation is Her/neu2, which is expressed in 90% of 
epithelial ovarian cancers. A phase I/II study conducted BY Chu et al. demonstrated 
a 90% 3-year overall survival response in patients with advanced ovarian cancer 
who were remission for vaccination with monocyte-derived dendritic cells (DC) 
loaded with Her2/neu, hTERT, and PADRE peptides, with or without low-dose 
intravenous cyclophosphamide [79].
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In a phase I/II study by Baek et al., 10 ovarian cancer patients with minimal 
residual disease were treated with dendritic cell vaccination with IL2. Three out 
of 10 patients showed maintenance of complete response, and one patient showed 
stable disease [80].
A phase II study was conducted to study the efficacy of personalized peptide 
vaccine (PPV) for recurrent ovarian cancer patients by Kawano et al. [81]. The 
patients enrolled in this study showed an overall survival (OS) of 39.3 months in 
platinum-sensitive cases and 16.2 months in platinum-resistant cases. This was 
attributed to be secondary to the stabilization of disease and the prolongation of 
tumor progression rather than disease regression.
7.3 Adoptive cell transfer in ovarian cancer
Adoptive cell transfer therapy is not widely studied in ovarian cancers. In a 
Japanese study by Fujita et al., 13 patients with epithelial ovarian cancer were 
treated with tumor-infiltrating lymphocyte therapy. Eleven patients served as 
control group who received only chemotherapy following primary operation. The 
estimated 3-year overall survival rate of disease-free patients in the TIL group and 
in the control group was 100 and 67.5%, respectively [82].
Vulvar and vaginal cancer: Immunotherapy has shown promising results in 
advanced gynecological cancer. Checkmate 358 trial has shown that nivolumab has 
encouraging clinical activity in cases of HPV-positive vulvar and vaginal malignan-
cies. A lot of research is warranted to establish immunotherapy as emerging treat-
ment option in these cancers.
8. Conclusion
Immunotherapy is emerging as a viable treatment modality in multiple cancers, 
and its safety and efficacy are under investigation in advanced gynecological malig-
nancies. Immune checkpoint inhibitors have shown promising preliminary results 
in advanced ovarian, cervical, and endometrial cancer.
© 2020 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
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